Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

316

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Aumolertinib
DRUG: Osimertinib

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]
[object Object]